PATEL SUJAL M (CEO, President, and Secretary) purchased 0.1% of their position (14.47K shares) of NAUTILUS BIOTECHNOLOGY, INC. on the open market
Open‑market purchase worth $41.5K — a small addition. The strongest form of insider conviction signal.
P · 2 purchases
Filed: 3/11/2024ACC: 0001808805-24-000026
DirectorOfficer10% Owner· CEO, President, and Secretary
Since Jun 2021
+14.47K
Net shares
Net buyer
$41.5K
Total acquired
2
Open market trades
2B · 0S
2
Total transactions
14.47K acquired
Non-Derivative Transactions2
Common Stock
Direct
Shares
+2.43K
Price / share
$2.99
Trade value
$7.26K
% of position
0.0%
3/8/2024
10.05M→10.05M
Common Stock
Direct
Shares
+12.04K
Price / share
$2.84
Trade value
$34.22K
% of position
0.1%
3/11/2024
10.05M→10.06M
Total
Net shares
+14.47K
Net value
$41.48K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/8/2024 | P · Purchase | +2.43K | $2.99 | $7.26K | 0.0% | 10.05M | 10.05M |
| Common Stock Direct | 3/11/2024 | P · Purchase | +12.04K | $2.84 | $34.22K | 0.1% | 10.05M | 10.06M |
| Total | +14.47K | $41.48K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)2
Common Stock
IndirectShares owned5.28M
Common Stock
IndirectShares owned1.81M
Total
7.09M indirect7.09M
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 5.28M | Indirect |
| Common Stock | 1.81M | Indirect |
| Total | 7.09M | 7.09M indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported